Mycobacterial Diseases
Open Access

Kutsyna GA

Publications

• Research Article
  Therapeutic Vaccination of Treatment-Failed TB Patients on “Palliative&trdquo; Support Consisting of Isoniazid and Rifampicin
  Author(s): Arjanova OV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Stepanenko AL, Butova TS, Jirathitikal V, Bourinbaiar AS and Kutsyna GAArjanova OV, Butov DA, Prihoda ND, Zaitzeva SI, Yurchenko LV, Sokolenko NI, Stepanenko AL, Butova TS, Jirathitikal V, Bourinbaiar AS and Kutsyna GA
  
  Open label phase 2b retrospectively controlled trial was conducted in 72 treatment-failed TB patients on socalled palliative support consisting of isoniazid (H) and rifampicin (R) with or without adjunct immunotherapy. The intervention group (N=36) received once-daily pill of V-5 Immunitor (V5) and comparison control (N=36) received HR only. The subjects in V5 and control groups had miliary: cavitary: MDR-TB: DR-TB: TB/HIV at 10: 26: 5: 4: 1 and 14: 22: 6: 6: 2 ratios, respectively. After 3 months 69.4% of V5-treated patients experienced negative sputum smear conversion (P<0.0001) vs. 16.7% (P=0.02) in comparison group who were treated for 3.5 months on average. 9 out of 10 V5 recipients with drug-resistant TB and TB/HIV became sputum negative, whereas none of 14 patients with same diagnosis converted (P<0.0001; OR 1732; 100-30008 at 95% CI). TB-associated inflammation was downr.. View More»
  DOI: 10.4172/2161-1068.S1-001

  Abstract PDF

Relevant Topics